Buspirone as a Candidate Medication for Methamphetamine Abuse
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 2/9/2018 |
| Start Date: | April 2013 |
| End Date: | March 2017 |
Methamphetamine use disorders are an unrelenting public health concern. Intensive research
efforts have yielded behavioral interventions that reduce methamphetamine use, however, these
interventions are not universally effective and treatment effects diminish over time.
Development of a pharmacotherapy that enhances the efficacy of these interventions is a
priority for the National Institute on Drug Abuse. This study proposes to determine the
impact of buspirone maintenance on self-administration of methamphetamine. These preliminary
data will be used to support further research developing buspirone as a pharmacotherapy for
methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate
the reinforcing effects of methamphetamine.
efforts have yielded behavioral interventions that reduce methamphetamine use, however, these
interventions are not universally effective and treatment effects diminish over time.
Development of a pharmacotherapy that enhances the efficacy of these interventions is a
priority for the National Institute on Drug Abuse. This study proposes to determine the
impact of buspirone maintenance on self-administration of methamphetamine. These preliminary
data will be used to support further research developing buspirone as a pharmacotherapy for
methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate
the reinforcing effects of methamphetamine.
Inclusion Criteria:
- Lifetime methamphetamine use
Exclusion Criteria:
- Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians
deem clinically significant
- Current or past histories of substance abuse or dependence that are deemed by the
study physicians to interfere with study completion
- History of serious physical disease, current physical disease, impaired cardiovascular
functioning, chronic obstructive pulmonary disease, history of seizure or current or
past histories of serious psychiatric disorder that in the opinion of the study
physician would interfere with study participation will be excluded from participation
- Females not currently using effective birth control
- Contraindications to methamphetamine or buspirone
We found this trial at
1
site
740 South Limestone Street
Lexington, Kentucky 40536
Lexington, Kentucky 40536
Principal Investigator: Craig R Rush, Ph.D.
Phone: 859-257-5388
Click here to add this to my saved trials
